000 | 01981 a2200565 4500 | ||
---|---|---|---|
005 | 20250513050541.0 | ||
264 | 0 | _c19950407 | |
008 | 199504s 0 0 eng d | ||
022 | _a0732-183X | ||
024 | 7 |
_a10.1200/JCO.1995.13.3.610 _2doi |
|
040 |
_aNLM _beng _cNLM |
||
100 | 1 | _aCrist, W | |
245 | 0 | 0 |
_aThe Third Intergroup Rhabdomyosarcoma Study. _h[electronic resource] |
260 |
_bJournal of clinical oncology : official journal of the American Society of Clinical Oncology _cMar 1995 |
||
300 |
_a610-30 p. _bdigital |
||
500 | _aPublication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S. | ||
650 | 0 | 4 | _aAdolescent |
650 | 0 | 4 | _aAdult |
650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
650 | 0 | 4 | _aChild |
650 | 0 | 4 | _aChild, Preschool |
650 | 0 | 4 | _aCombined Modality Therapy |
650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
650 | 0 | 4 |
_aDactinomycin _xadministration & dosage |
650 | 0 | 4 | _aDisease-Free Survival |
650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
650 | 0 | 4 |
_aEtoposide _xadministration & dosage |
650 | 0 | 4 | _aFemale |
650 | 0 | 4 | _aHumans |
650 | 0 | 4 | _aInfant |
650 | 0 | 4 | _aMale |
650 | 0 | 4 | _aPrognosis |
650 | 0 | 4 | _aRemission Induction |
650 | 0 | 4 |
_aRhabdomyosarcoma _xdrug therapy |
650 | 0 | 4 | _aSurvival Rate |
650 | 0 | 4 | _aUnited Kingdom |
650 | 0 | 4 | _aUnited States |
650 | 0 | 4 |
_aVincristine _xadministration & dosage |
700 | 1 | _aGehan, E A | |
700 | 1 | _aRagab, A H | |
700 | 1 | _aDickman, P S | |
700 | 1 | _aDonaldson, S S | |
700 | 1 | _aFryer, C | |
700 | 1 | _aHammond, D | |
700 | 1 | _aHays, D M | |
700 | 1 | _aHerrmann, J | |
700 | 1 | _aHeyn, R | |
773 | 0 |
_tJournal of clinical oncology : official journal of the American Society of Clinical Oncology _gvol. 13 _gno. 3 _gp. 610-30 |
|
856 | 4 | 0 |
_uhttps://doi.org/10.1200/JCO.1995.13.3.610 _zAvailable from publisher's website |
999 |
_c7883758 _d7883758 |